Bioavailability investigation of two different oral formulations of methylprednisolone

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 3, 2000, Pages 286-292

  Geister, Ursula ^a   Guserle, Richard ^a   Bungers, Eva ^a   Schaarschmidt, Dieter ^b   Doser, Karlheinz ^c  

^a Pharmakin GmbH   (Germany)

^b PHAROS GmbH   (Germany)

^c ratiopharm GmbH   (Germany)

Author keywords

Bioavailability; Bioquivalence; CAS 83 43 2; High pressure liquid chromatography; Methylprednisolone; Methylprednisolone ratiopharm

Indexed keywords

METHYLPREDNISOLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

EID: 0034106012     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300201     Document Type: Article

References (16)

1. [1] Martindale, The Extra Pharmacopoe, 32nd ed., p. 1118, 1983, Pharmaceutical Press, London (1999)
2. [2] Rohatagi, S., Barth, J., Hochhams, G. et al., Pharmacokinetics of Methylprednisolone and Prednisolone After Single and Multiple Oral Administration, Clin. Pharmacol. 37, 916-925 (1997)
3. [3] Garg, D. C., Wagner, J. G., Sakmar, E. et al., Rectal and oral absorption of methylprednisolone acetate, Clin. Pharmacol. Ther. 26, 232 (1979)
4. [4] Tornatore, K. M., Logue, G., Venuto, R. C. et al., Pharmacokinetics of Methylprednisolone in Elderly and Young Healthy Males, J. Am. Geriat. Soc. 42, 1118 (1994)
5. [5] Barth, J., Möllmann, H. W., Wagner, T. et al., Problematik des Äquivalenzbegriffes bei der Therapie mit Glucocorticoiden, Dtsch. med. Wochenschr. 119, 1671 (1994)
6. [6] Antal, E. J., Wright, C. E., III, Gillespie, W. R. et al., Influence of Route of Administration on the Pharmacokinetics of Methylprednisolone, J. Pharmacokin. Biopharm. 11, 561 (1983)
7. [7] Al-Habet, S. M. H., Rogers, H. J., Methylprednisolone pharmacokinetics after intravenous and oral administration, Br. J. Clin. Pharmacol. 27, 285 (1989)
8. [8] Fachinformation Urbason® Tabletten (204 143), Hoechst Marion Roussel, Bad Soden/Ts.(1998)
9. [9] Szefler, S. J., Ebling, W. F., Georgitis, J. W. et al., Methylprednisolone Versus Prednisolone Pharmacokinetics in Relation to Dose in Adults, Eur. J. Clin. Pharmacol. 30, 323 (1986)
10. [10] Mollmann, H., Rohdewald, P., Barth, J. et al., Pharmacokinetics and dose linearity testing of methylprednisolone phosphate, Biopharm. Drug Dispos. 10, 453 (1989)
11. [11] Philipson, R. S., House, E. S. A, Smith, J. T. L., A study to evaluate dose linearity and relative bioavailability of oral methylprednisolone, Pharm. Res. 14, 607 (1997)
12. [12] Shah, V. P., Midha, K. K., Dighe, S. et al., Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies, J. Pharm. Sci. 81, 309 (1992)
13. [13] Diletti, E., Hauschke, D., Steinijans, V. W., Sample size determination for bioequivalence assessment by means of confidence intervals. Int. J. Clin. Pharmacol. Ther. Toxicol. 30 (Suppl. 1), 51 (1992)
14. [14] CPMP-note for guidance III/54/89-EN, Final, December 1991 "Investigation of Bioavailability and Bioequivalence", European Agency for the Evaluation of Medicinal Product, London (1991)
15. [15] Gardner, S., Bioavailability and bioequivalence requirements. Procedures for establishing a bioequivalence requirement, Fed. Reg. 42, 1624 (1977)
16. [16] Schulz, H.-U., Steinijans, V. W., Striving for standards in bioequivalence assessment. A review, Int. J. Pharmacol. Ther. Toxicol. 29, 293 (1991)